Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2012-03-19
Original market date: See footnote 1
2012-03-19
Product name:
HALAVEN
Description:
2ML SINGLE USE VIAL
DIN:
02377438
Product Monograph/Veterinary Labelling:
Date:
2017-08-04
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
EISAI LIMITED
6925 Century Ave, Suite 701
Mississauga
Ontario
Canada
L5N 7K2
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Intravenous
Number of active ingredient(s):
1
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
10:00.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
L01XX41 ERIBULIN
Active ingredient group (AIG) number:See footnote5
0153064001
| Active ingredient(s) | Strength |
|---|---|
| ERIBULIN MESYLATE | 0.5 MG / ML |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.